Table 5 |
||||
|
Time to first response (days) in intention-to-treat population, according to initial masitinib dosage |
||||
|
Parameter |
3 mg/kg per day (n = 22) |
6 mg/kg per day (n = 18) |
Total population (n = 40) |
P value |
|
|
||||
|
ACR20 |
||||
|
Patients |
12/22 (55.0%) |
11/18 (61.0%) |
23/40 (57.5%) |
0.213 |
|
Mean ± SD |
51.9 ± 24.5 |
40.3 ± 19.0 |
46.3 ± 22.4 |
|
|
Median |
56.0 |
29.0 |
35.0 |
|
|
Range |
28.0–105.0 |
28.0–86.0 |
28.0–105.0 |
|
|
ACR50 |
||||
|
Patients |
7/22 (32.0%) |
8/18 (44.0%) |
15/40 (37.5%) |
0.771 |
|
Mean ± SD |
91.9 ± 59.5 |
86.8 ± 61.1 |
89.1 ± 58.2 |
|
|
Median |
84.0 |
72.5 |
84.0 |
|
|
Range |
28.0–217.0 |
28.0–203.0 |
28.0–217.0 |
|
|
|
||||
|
ACR20, American College of Rheumatology 20% improvement criteria; ACR50, American College of Rheumatology 50% improvement criteria; SD, standard deviation. |
||||
|
Tebib et al. Arthritis Research & Therapy 2009 11:R95 doi:10.1186/ar2740 |
||||
